Metabolic Syndrome Clinical Trial
Official title:
Understanding Components of Mind-body Exercise for Physical Activity Engagement in Metabolic Syndrome
The aim of this study is to assess the feasibility and acceptability (e.g., enrollment, adherence, retention, acceptability of procedures and interventions) of a pilot factorial study design that will help elucidate components of mind-body exercise interventions. The study involves completing a walking program, a mindful attention program, a walking program that includes mindful attention, or no program at all. A "pilot" study is a smaller study that helps researchers to understand whether the study design can be carried out and what participants think about the study.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 2026 |
Est. primary completion date | April 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Metabolic syndrome, defined as meeting 3 or more of the following criteria in the last 12 months at the time of medical record review: (a) BMI = 25; (b) fasting glucose = 100 [5.6 mmol/L] or A1C = 5.7 or medications; (c) blood pressure = 130 systolic or = 85 diastolic or medications; (d) triglycerides = 150 or 1.7 mmol/L or medications; (e) or HDL < 40mg/ dL for men and 50mg/dL for women or medications; - insufficiently active, defined as a score = 23 (moderate-to-strenuous units) on Godin-Shepard Leisure-Time Physical Activity Questionnaire; - age 18-70 years; - given medical clearance for moderate-intensity exercise and exercise stress testing by their primary care physician (PCP); - access to a device with internet and videoconferencing capabilities Exclusion Criteria: - current diagnosis of any of the following: (a) coronary artery disease or other chronic heart diseases (e.g., heart failure) in which exercise would be contraindicated or that would preclude HRV analyses (e.g., some arrhythmias); (b) any diabetes; (c) chronic obstructive pulmonary disease or other severe lung dysfunction (e.g., severe asthma); (d) severe cognitive impairment - >2 self-reported classes or self-guided mindfulness or mindful movement sessions per week in past 3 months - self-reported inability to speak and read in English - current beta blocker or calcium channel blocker medication - uncontrolled hypertension, defined as resting blood pressure = 150 systolic or = 90 diastolic in the last 6 months - self- or physician-reported contraindications for exercise (e.g., severe balance impairment, musculoskeletal restrictions) |
Country | Name | City | State |
---|---|---|---|
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Beth Israel Deaconess Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of screening: screened to eligible ratio | percent of screened individuals that were determined eligible for the study | Through study completion, an average of 1 year | |
Primary | Feasibility of enrollment: eligible to enrollment ratio | percent of eligible individuals that enroll in the study; determined to be feasible if greater than or equal to 70% of eligible patients enroll | Through study completion, an average of 1 year | |
Primary | Feasibility of retention: retention at each assessment | percent of enrolled participants retained at post-intervention and 3-month follow-up; determined to be feasible if greater than or equal to 70% retention at each assessment | 6 months | |
Primary | Feasibility of interventions: attendance rates for each session | percent session attendance; determined to be feasible if participants attend greater than or equal to 75% of sessions | 6 months | |
Primary | Feasibility of survey completion: survey completion rates at each assessment | percent of participants that complete surveys at post-intervention and 3-month follow-up | 6 months | |
Primary | Acceptability of interventions | Acceptability of the interventions will be assessed via overall satisfaction (1 = not at all to 10 = very much); determined to be acceptable if mean rating is greater than or equal to 7.5 across 80% of sessions | 6 months | |
Primary | Acceptability of study design | Acceptability of the study design will be assessed via acceptability of study procedures (1= not at all to 10 = very much); determined to be acceptable if mean rating is greater than or equal to 7.5 across 80% of sessions | 6 months | |
Primary | Perspectives on study interventions | Perspectives on study interventions will be assessed via exit interview | Post-intervention (after 8 week intervention) | |
Secondary | Ventilatory efficiency | Assessed via a maximal cardiopulmonary exercise test, using expired gas analysis under continuous electrocardiographic monitoring. | Baseline (week 0), post-intervention (after 8 week intervention) | |
Secondary | Heart rate dynamics | Assessed via 24-hour heart rate monitoring | Baseline (week 0), post-intervention (after 8 week intervention) | |
Secondary | Positive affect | Positive and Negative Affect Schedule, a validated self-report measure, used to assess levels of positive affect. The positive affect subscale is made up of 10 items rated on a 5-point Likert scale. Scores range from 10 to 50 with higher scores indicating greater levels of positive affect | Baseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention | |
Secondary | Emotion regulation | Difficulties in Emotion Regulation Scale, a 36-item validated self-report measure, used to assess difficulties with emotion regulation; items are rated on a 5-point Likert scale, total scores range from 36 to 180, with higher scores reflecting greater emotion regulation difficulties. 6 subscale scores with higher scores reflecting greater emotion regulation difficulties. | Baseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention | |
Secondary | Interoceptive awareness | Multidimensional Assessment of Interoceptive Awareness Scale, a 32-item validated self-report measures, used to assess levels of interoceptive awareness; items are rated on a 6-point Likert scale, total scores range from 0 to 160, with higher scores reflecting greater interoceptive awareness. 8 subscales with higher scores reflecting greater interocpetive awareness | Baseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention | |
Secondary | Self-efficacy | Multidimensional Self-Efficacy Scale, a 9-item validated self-report measure, used to assess levels of self-efficacy; scores range from 0-90 with higher scores reflecting greater self-efficacy | Baseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention | |
Secondary | Self-reported physical activity | International Physical Activity Questionnaire, a validated self-report measure, used to assess levels of physical activity; walking MET mins/week, moderate MET mins/week and vigorous MET mins/week are calculated | Baseline (week 0), post-intervention (after 8 week intervention), 3 months post-intervention | |
Secondary | Objective physical activity | 7 day activity monitoring (via ActiGraph monitor) to assess minutes per week in moderate-intensity exercise | Baseline (week 0), post-intervention (after 8 week intervention) | |
Secondary | In-session oxygen consumption | Submaximal cardiopulmonary exercise testing (via standard metabolic cart) | Weeks 1 and 8 | |
Secondary | In-session ventilatory efficiency | Submaximal cardiopulmonary exercise testing (via standard metabolic cart) | Weeks 1 and 8 | |
Secondary | In-session respiration rate | Submaximal cardiopulmonary exercise testing (via standard metabolic cart) | Weeks 1 and 8 | |
Secondary | In-session heart rate | Submaximal cardiopulmonary exercise testing (via standard metabolic cart) | Weeks 1 and 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |